摘要
背景与目的:肺癌是当前世界最常见的恶性肿瘤之一,由于症状隐匿,往往就诊时已是晚期。本研究的目的是为了比较多西他赛及吉西他滨联合顺铂一线治疗晚期非小细胞肺癌的疗效和不良反应。方法:103例晚期非小细胞肺癌患者随机分为2组。多西他赛组:多西他赛37.5mg/m2,第一天、第八天,顺铂75mg/m2,第一天至第三天。吉西他滨组:吉西他滨1000mg/m2,第一天、第八天,顺铂用量同前。化疗每3周重复,每周期评价不良反应,生活质量,两周期后评价疗效并随访生存期。结果:多西他赛组有效率46%,1年生存率48%,3年生存率10%。吉西他滨组有效率43.4%,1年生存率47.2%,3年生存率9.4%(P>0.05)。两组主要毒副作用为骨髓抑制、恶心、呕吐。结论:一线治疗晚期非小细胞肺癌多西他赛和吉西他滨联合顺铂疗效高,生存期长。
Background and purpose： Lung cancer is one of the most common diseases worldwide. The majority of patients have advanced lung cancer when they were initially diagnosed. We compared the efficacy and safty of docetaxel/cisplatin regiment and gecitabine/cisplatin regiment in the treatment of advanced non-small cell lung cancer（NSCLC）. Methods： A total of 103 patients with advanced NSCLC were divided into 2 groups. The patients received docetaxel 37.5 mg/m^2 on day 1 and 8, cisplatin 75 mg/m^2 on day 1 to day 3 in docetaxel group.ln gemcitabine group the patients received gemcitabine 1 000 mg/m^2 on day 1 and day 8, and the same dosage of cisplatin as in docetaxel group. The treatment schedule was recycled every 3 weeks. The toxicity and quality of life were evaluated after every cycle. The treatment response and survival rate were evaluated by the end of two cycles. Results： The response rates of docetaxel group and gemcitabine group were 46% and 43.4%, respectively. Median survival rate in the two groups were 10.7 and 10.9 months, respectively.Comparing the two groups, 1 and 3 year survival rate were 48% and 10%, 47.2% and 9.4%, respectively（P〉0.05）. The mainly side-effects were myelosuppression, nausea, and vomiting. Conclusions： Docetaxel/cisplatin and gemcitabine/cisplatin regimens were well toleranced in advanced NSCLC patients with long term survival.
出处
《中国癌症杂志》
CAS
CSCD
2008年第7期531-534,共4页
China Oncology
关键词
非小细胞肺癌
化疗
多西他赛
吉西他滨
顺铂
non-small cell lung cancer
chemotherapy
docetaxel
gemcitabine
cisplatin
